Ronald Magee, MD
Vascular Surgery · Oklahoma City, OKNPI 1013918317
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.2% of the total across 135 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by Endologix LLC at 36.5% of the total. That places this record below the midpoint for vascular surgery clinicians in OK, where the typical reported total is $6,612.
Across 135 payments — averaging $44.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Endologix LLC$2K
- Silk Road Medical, Inc.$1K
- Surmodics, Inc.$574
- Shockwave Medical, Inc$354
- W. L. Gore & Associates, Inc.$333
- Johnson & Johnson$304
- plus $829 from 19 others
What the payments were for
- Travel & lodging$59210%
- Food & beverage$5,47490%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Endologix LLC | 10 | $2,212 |
| Silk Road Medical, Inc. | 30 | $1,459 |
| Surmodics, Inc. | 25 | $574 |
| Shockwave Medical, Inc | 3 | $354 |
| W. L. Gore & Associates, Inc. | 3 | $333 |
| Johnson & Johnson | 18 | $304 |
| Acera Surgical, Inc. | 7 | $154 |
| Organogenesis Inc. | 10 | $119 |
| Pfizer | 4 | $72 |
| Novartis | 3 | $58 |
| Merck | 4 | $57 |
| E.r. Squibb & Sons, L.L.C. | 3 | $55 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $48 |
| Philips North America LLC | 1 | $44 |
| Amgen | 2 | $36 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Innovation Technologies Inc | 1 | $25 |
| Acell, Inc. | 1 | $23 |
| Cook Medical LLC | 1 | $21 |
| KCI USA, Inc. | 1 | $18 |
| Boston Scientific | 1 | $17 |
| AstraZeneca | 1 | $15 |
| Inari Medical, Inc. | 1 | $14 |
| Lemaitre Vascular, Inc. | 1 | $14 |
| Getinge USA Sales, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ovation$997
- ENROUTE Transcarotid Stent$873
- ENROUTE Transcarotid Neuroprotection System$873
- Alto Abdominal Stent Graft System$766
- AFX2 Bifurcated Endograft System$448
- AFX2$393
- AFX$334
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$311
- Ovation iX Iliac Stent Graft$200
- GORE TAG Conformable Thoracic Endoprosthesis$163
- GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis$151
- Sublime 014 Rx PTA Balloon Dilatation Catheter$124
- Sublime Microcatheter, 018, 200cm, Straight$124
- Pounce Thrombectomy System$124
- Pounce Thrombectomy$124
- Pounce Venous Thrombectomy System$124
How this compares
$6,066 in reported general payments places this provider in the 40th percentile of 35 vascular surgery providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 34 | $19,991 |
| ClopidogrelClopidogrel Bisulfate | 312 | $3,717 |
| Cilostazol | 73 | $1,675 |
| Enoxaparin Sodium | 12 | $803 |
| Warfarin Sodium | 67 | $660 |
| Atorvastatin Calcium | 28 | $469 |
| Gabapentin | 26 | $402 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 27 | $215 |
| Rosuvastatin Calcium | 12 | $72 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $72 | $19,99134 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 35 vascular surgery providers in Oklahoma.
Other vascular surgery in Oklahoma City
- Jim MeltonOklahoma City$131K
- Lenny StubbsOklahoma City$56K
- Ali AminOklahoma City$41K
- Bernardino RochaOklahoma City$34K
- Clifford HowellOklahoma City$17K
- Sherisa WarrenOklahoma City$15K
- Jones ThomasOklahoma City$14K
- Trenton KinnearOklahoma City$10K
- Donald SpadoneOklahoma City$9K
- James NeelOklahoma City$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.